Hypertension Center

Controversies in Renal Denervation

Perspectives on key discussion points in renal denervation, including recommended blood pressure targets and documentation, patient monitoring, changes in practice patterns, data needed to drive increased adoption, and lessons learned from the European experience.

With Joseph E. Ebinger, MD, MS, FACC; Maria Carolina Delgado-Lelievre, MD; Atul Chugh, MD, FACC, RPVI; Brian C. Bigelow, MD, FACC, FSCAI, FSVM; Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM; and Joachim Weil, MD

Renal Denervation in Prime Time

By Taisei Kobayashi, MD

The Future of Denervation Technologies

Advances in device platforms for hypertension, access strategies, multiorgan denervation, and emerging applications in hypertension and cardiometabolic disease.

By Shukri W. David, MD, MBA, and Herbert D. Aronow, MD, MPH

The Financial Landscape of Renal Denervation

How reimbursement and evolving coverage policies are defining access to renal denervation.

By Catherine Vanchiere, MD, MA; Tayyab Shah, MD; Maria Bonanni, CRNP; Debbie L. Cohen, MD; Jay S. Giri, MD, MPH; and Brian Fulton, MD

Renal Denervation: Review of Contemporary Data and the Road to Mainstream Adoption

Current clinical evidence, guideline updates, practical considerations, and evolving device-based therapies for renal denervation in hypertension management.

By Aditi Ujjawal, MD; Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM; and Anna K. Krawisz, MD

Building Multidisciplinary Teams in Interventional Cardiology

Exploring the benefits and challenges of a multispecialty team approach to optimize patient outcomes in the areas of pulmonary embolism, renal denervation, limb salvage, and carotid disease.

With Matthew Finn, MD, MSc, and Jun Li, MD

Expanding Horizons in Interventional Cardiology

By Christine J. Chung, MD

Next Frontiers in HTN Denervation

Reflections on the next generation of RDN trials and their potential endpoints, how to handle data collection, and new applications beyond renal.

With Felix Mahfoud, MD, MA; Ajay J. Kirtane, MD; and Andrew Sharp, MD

The State of Reimbursement for Renal Denervation in the United States

As renal denervation is adopted across the United States for patients with uncontrolled or resistant hypertension, the dubious state of reimbursement presents a barrier to both health systems and patients seeking the procedure.

By Catherine Vanchiere, MD, MA; Tayyab Shah, MD; Debbie L. Cohen, MD; Jay Giri, MD, MPH; Brian Fulton, MD; and Taisei Kobayashi, MD

HTN Practice and Team Building

Early adopters/referrers of RDN for hypertension discuss keys to successfully starting a dedicated practice, advice for developing referrer relationships, tips for reaching patients, and more.

With Tiffany C. Randolph, MD, MHA, FACC; Michael J. Bloch, MD, FAHA, FASH, FNLA, FSVM, FACP; and Anna K. Krawisz, MD

Radiation and Musculoskeletal Safety

By Eric A. Secemsky, MD, MSc

An Interview With Felix Mahfoud, MD, MA

Prof. Mahfoud breaks down his translational cardiology research focused on the autonomic nervous system and interorgan communication in cardiovascular disease, remaining hurdles and research priorities for renal denervation, his work with the ESC and EAPCI, and more.

An Interview With Faisal Sharif, MD, PhD, FESC, FACC, FRCPI

Prof. Sharif shares what “translational cardiovascular medicine” looks like in practice, his work with CURAM and BioInnovate, insights from running an RDN center of excellence, and more.

Step-by-Step Approach to Balloon Pulmonary Angioplasty for CTEPH

Best practices for the technical execution of safe and effective BPA.

By Ahmad Jabri, MD; Anas Alameh, MD; Bryan Kelly, DO; and Vikas Aggarwal, MD, MPH

Key Questions for Ongoing and Future Renal Denervation Trials

Dr. Ajay J. Kirtane discusses where renal denervation devices fit in the blood pressure control landscape, remaining questions to be addressed, ensuring patient access to this therapeutic option, and ideal goals for future trials.

Ask The Experts: Lessons From the Renal Denervation Learning Curve

Experts share insights into lessons learned from clinical trials and real-world experience to date and the future of renal denervation.

With Herbert D. Aronow, MD, MPH; Michael Kunz, MD; Lucas Lauder, MD; and Felix Mahfoud, MD

Technical Essentials

By Andrea Scotti, MD, and Azeem Latib, MD

Renal Denervation: Where We Stand After the FDA Panels

Experts’ thoughts on what defines a clinically meaningful reduction in blood pressure, roles of office-based and ambulatory blood pressure monitoring, ideal candidates for renal denervation and patient preference as a driver for the procedure, options that could meet the FDA's request for more data, and applying a team-based approach to screening and treatment.

With Ajay J. Kirtane, MD, SM; Eric A. Secemsky, MD, MSc, RPVI, FACC, FSCAI, FSVM; and Taisei Kobayashi, MD

Curbside Consult: The Biggest Clinical Trial Innovation Needs in…

Physicians consider priorities for future clinical trials in their respective interventional cardiology areas of focus, with responses spanning from a need for data informing treatment benefit and decision-making for current and future therapies to broader changes needed in the approach to research.

With Mirvat Alasnag, MD, FACC, FACP, FSCAI, FRCP; Salvatore Brugaletta, MD, PhD; Jay Giri, MD, MPH, FACC, FAHA, FSCAI; Rasha Al-Lamee, MA, MBBS, FRCP, PhD; Rishi Puri, MD, PhD, FRACP; and Gagan D. Singh, MD